OncoMatch/Clinical Trials/NCT04799548
A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
Is NCT04799548 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Transcatheter Arterial Chemoembolization and Tislelizumab for advanced gastric cancer.
Treatment: Transcatheter Arterial Chemoembolization · Tislelizumab — This study is a phase II, prospective, single-center, single-arm trial to evaluate the efficacy and safety of the combination of neoadjuvant transcatheter arterial chemoembolization (TACE) and PD-1 antibody Tislelizumab in the locally advanced stomach adenocarcinoma. The primary purpose of this study is to evaluate the pathologic complete response (pCR) rate of TACE plus Tislelizumab. The second purpose is to evaluate pathologic response rate (pRR), objective Response Rate (ORR), overall survival (OS) and progression-free survival (PFS) of the patients enrolled in this study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage CT4AN+M0 (AJCC TNM 8th edition)
clinical staging is determined to be cT3/4aN+M0 (according to AJCC TNM 8th edition)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Exception: corticosteroids
Those who have received cytotoxic chemotherapy, radiotherapy, immunotherapy or radical surgery for the treatment of this gastric cancer, except for corticosteroids
Cannot have received: radiotherapy
Exception: corticosteroids
Those who have received cytotoxic chemotherapy, radiotherapy, immunotherapy or radical surgery for the treatment of this gastric cancer, except for corticosteroids
Cannot have received: immunotherapy
Exception: corticosteroids
Those who have received cytotoxic chemotherapy, radiotherapy, immunotherapy or radical surgery for the treatment of this gastric cancer, except for corticosteroids
Cannot have received: radical surgery
Exception: corticosteroids
Those who have received cytotoxic chemotherapy, radiotherapy, immunotherapy or radical surgery for the treatment of this gastric cancer, except for corticosteroids
Cannot have received: anti-PD-1 therapy
Have received anti-PD-1, anti-PD-L1, anti-PD-L2 or any other specific targeting T cell costimulation or checkpoint pathway antibodies or drug therapy
Cannot have received: anti-PD-L1 therapy
Have received anti-PD-1, anti-PD-L1, anti-PD-L2 or any other specific targeting T cell costimulation or checkpoint pathway antibodies or drug therapy
Cannot have received: anti-PD-L2 therapy
Have received anti-PD-1, anti-PD-L1, anti-PD-L2 or any other specific targeting T cell costimulation or checkpoint pathway antibodies or drug therapy
Cannot have received: checkpoint inhibitor
any other specific targeting T cell costimulation or checkpoint pathway antibodies or drug therapy
Cannot have received: immunotherapy (interleukin, interferon, thymosin)
Have received immunotherapy (such as interleukin, interferon, thymosin, etc.) or any trial treatment within 28 days or 5 half-lives (whichever is shorter, but at least 14 days) before enrollment
Cannot have received: palliative radiotherapy
Palliative radiotherapy was performed within 14 days before enrollment
Lab requirements
Blood counts
The blood routine and biochemical indexes of the subjects met standards within 7 days before enrollment
Kidney function
Moderate or severe renal damage [creatinine clearance equal to or lower than 50 ml/min (calculated according to the Cockroft and Gault equation)], or serum creatinine>ULN [excluded]
Liver function
The blood routine and biochemical indexes of the subjects met standards within 7 days before enrollment
The blood routine and biochemical indexes of the subjects met standards within 7 days before enrollment; Moderate or severe renal damage [creatinine clearance equal to or lower than 50 ml/min (calculated according to the Cockroft and Gault equation)], or serum creatinine>ULN [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify